Robert J. Morgan

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

Agustin A. García, Hal W. Hirte, Gini F. Fleming et al. · Journal of Clinical Oncology · 2007 · 549 citations

Medicine, Oncology, Pharmacology +16

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

Jonathan E. Zuckerman, Ismael Gritli, Anthony W. Tolcher et al. · Proceedings of the National Academy of Sciences · 2014 · 410 citations · Full text

Pharmacy, Oncology, Pharmaceutics +17

Nonrandom connectivity of the epileptic dentate gyrus predicts a major role for neuronal hubs in seizures

Robert J. Morgan, Iván Soltész · Proceedings of the National Academy of Sciences · 2008 · 349 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Robert J. Morgan, Deborah K. Armstrong, Ronald D. Alvarez et al. · Journal of the National Comprehensive Cancer Network · 2016 · 323 citations · Full text

Medicine, Gynecology, Oncology +17

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

Thehang Luu, Robert J. Morgan, Lucille Leong et al. · Clinical Cancer Research · 2008 · 236 citations · Full text

Medicine, Oncology, Pharmacology +17